Zai Lab ADR is not currently near a potential buy zone. See if the stock goes on to form a base that could spark a new run.

Zai Lab Limited (NASDAQ:ZLAB) said on Monday that it received U.S. FDA fast track designation for its antibody-drug conjugate, ZL-1310, for the treatment of extensive-stage small cell lung cancer.

Zai Lab accelerates innovative drug launches in China through partnerships and expertise, targeting $1.5-$2B revenue by 2028.

Zai Lab Limited is an innovative Pharma partnering with US and European Pharmas to secure approvals for, and market their drugs in China. ZLAB stock has surged over 105% in the past year ...